Copyright Live 5 News WCSC
WASHINGTON (Gray DC) - President Donald Trump is promising that he cost of two popular weight-loss drugs is coming down. Surrounded by pharmaceutical executives and his health advisors in the Oval Office, President Trump announced a deal that promises to dramatically cut the cost of two of America’s most popular weight-loss drugs. Under deals struck with the Trump Administration, Eli Lilly and Novo Nordisk that will soon lower the price of their weight-loss drugs, including Ozempic and Wegovy, for some patients who are covered by Medicare and Medicaid. “We’re covering this today because it’s such a big seller, and I guess it’s the number one selling thing there is today. These are two companies that are behind the groundbreaking weight loss drugs that have helped millions of Americans struggling with obesity live better, longer lives.” Starting somtime next year, Eli Lilly and Novo Nordisk will sell their weight-loss drugs to Medicare for $149 per month for the lowest dose and $245 per month for larger doses. The drugs also will be offered at discounted rates through the administration’s TrumpRx.gov website, which is expected to go live in 2026. “For years politicians have talked about making health care affordable, but my administration is actually doing it. Americans deserve the best health care in the world, and we’re now getting the best health care at the lowest price.” Under the deal, both drug companies will receive expedited reviews from the Food and Drug Administration for bringing new drugs to market. They will also get access to Medicare, which provides health coverage to about 70 million older Americans. Health advisors to the President say the deals could have a significant effect on Americans living with obesity. Both Wegovy and Ozempic are wild popular and they are also prohibitively expensive for most Americans. President Trump also revealed that his communications director, or head of public relations as Trump put it, Stephen Cheung is on the weight loss drugs.
